



PHYSICIAN THERAPEUTICS

Targeted Cellular Technology®

Targeted Medical Pharma Awarded \$733,429.00 in Qualifying New Therapeutic Discovery Grants

Grants Cover *Theramine®*, *Sentra PM®*, *Sentra AM®* and *GABAdone®*

Los Angeles, CA, Nov. 1, 2010 /**Targeted Medical Pharma Inc.** a Specialty Pharma company developing proprietary medical food products distributed through subsidiary **Physician Therapeutics** announced it has been awarded \$733,429.00 in government grants. Under the recently enacted Patient Protection and Affordable Care Act, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed significant potential in producing new and cost-saving therapies, support job growth and increase U.S. competitiveness. Grants were awarded through a competitive application process supervised by the National Institutes of Health. All three of the Company's applications were awarded. The first involved the reduction of gastrointestinal hemorrhage by **Theramine** associated with treatment of back pain syndromes. The second involves reduction of the side effects associated with sleep disorders in the elderly with **Sentra PM** and **GABAdone**, and the third addresses a safe and effective treatment for symptoms of Gulf War Illness with **Sentra PM** and **Sentra AM**. The Company will be able to expand the growth of these and other innovative products with these funds.

About Targeted Medical Pharma Inc.

Targeted Medical Pharma Inc. is a leader in the development of therapeutic systems for the nutritional management of chronic diseases. The Company strives to optimize patient care with safe and clinically effective prescription Medical Food products, such as **Theramine®**, **GABAdone®**, **Sentra AM®**, **Sentra PM®**, **Trepadone®**, and **Hypertensa®**, as well as distributing generic and branded drugs through subsidiary company, **Physician Therapeutics**.

Source: Targeted Medical Pharma Inc.